Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Previous studies have identified that lens epithelium-derived growth factor (LEDGF) interacts with SETD2-dependent histone H3 trimethylated at lysine 36 (H3K36me3) to mediate transcriptional elongation. However, the original LEDGF recognition H3K36me3 epigenetic regulatory axis no longer exists in SETD2 mutant clear cell renal cell carcinoma (ccRCC) patients, and a new transcription system needs to be discovered. In this study, the authors demonstrated the novel interaction between LEDGF and H3R17me2a. In detail, Asn38 and Asp57 of LEDGF Proline-Tryptophan-Tryptophan-Proline (PWWP) domain are the key binding sites validated by peptide pull-down assays. Subsequently, a series of in vitro and in vivo experiments showed that PPAT, PAICS, GART, ADSL, and ADSS2 are key target genes. Collectively, LEDGF binds H3R17me2a to regulate purine nucleotide metabolism in SETD2 mutant ccRCC cells, promoting tumor proliferation, and may be an effective therapeutic target.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/advs.202416809 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Co-operative epigenetic remodelling by Setd2 deficiency and Kras mutation drives juvenile myelomonocytic leukaemia development and MEK inhibitor sensitivity.
Br J Haematol
August 2025
Department of Haematology, National & Local Joint Engineering Research Center of Biodiagnosis and Biotherapy, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, People's Republic of China.
Juvenile myelomonocytic leukaemia (JMML) primarily stems from the Rat Sarcoma (RAS)/Extracellular Signal-Regulated Kinase (ERK) pathway mutations, and currently, there are no effective regimens against JMML, yet various studies have highlighted the importance of deciphering secondary genetic and/or epigenetic alterations in pursuit of treatments. Setd2-mediated-H3K36me3 participates in myriad biological functions and primarily serves as a tumour suppressor gene in carcinogenesis. However, little is known about the synergism between Setd2 deficiency and Kras mutation during JMML onset and progression.
View Article and Find Full Text PDFObjective: Seizure is frequently a presenting symptom for patients with diffuse glioma, and seizures can remain common throughout the disease course. Patients can develop seizures despite resection, and the relationship among postoperative seizures, tumor genetics, and tumor progression is unclear. The aim of this study was to characterize the clinical and genetic factors associated with delayed postoperative seizures in adult patients who had undergone resection of diffuse gliomas and to investigate the relationship between time to seizure onset and progression-free survival (PFS).
View Article and Find Full Text PDFLEDGF Binds H3R17me2a Promoting De Novo Nucleotide Biosynthesis in SETD2 Mutant Clear Cell Renal Cell Carcinoma.
Adv Sci (Weinh)
June 2025
Medical School of Nantong University, 9 Qiangyuan Road, Nantong, 226019, China.
Previous studies have identified that lens epithelium-derived growth factor (LEDGF) interacts with SETD2-dependent histone H3 trimethylated at lysine 36 (H3K36me3) to mediate transcriptional elongation. However, the original LEDGF recognition H3K36me3 epigenetic regulatory axis no longer exists in SETD2 mutant clear cell renal cell carcinoma (ccRCC) patients, and a new transcription system needs to be discovered. In this study, the authors demonstrated the novel interaction between LEDGF and H3R17me2a.
View Article and Find Full Text PDFPurpose: The mammalian target of rapamycin (mTOR) inhibitor everolimus is US Food and Drug Administration-approved for advanced pancreatic neuroendocrine neoplasms (pNENs), yet resistance is common, necessitating the identification of resistance mechanisms for effective treatment strategies. Previous studies suggest that targeting the aberrant expression of mTOR regulators p21-activated kinase 4 (PAK4) and nicotinamide phosphoribosyl transferase (NAMPT) sensitizes pNENs to everolimus. In this study, we queried a large real-world data set of pNENs, characterizing the molecular and immune landscapes, as well as the clinical outcomes associated with aberrant PAK4 and NAMPT expression.
View Article and Find Full Text PDFIntegrated Computational and Functional Screening Identifies G9a Inhibitors for SETD2-mutant Leukemia.
Genomics Proteomics Bioinformatics
May 2025
China National Center for Bioinformation, Beijing 100101, China.
SETD2, a frequently mutated epigenetic tumor suppressor gene in acute leukemia, is associated with chemotherapy resistance and poor patient outcomes. To explore potential therapeutics for SETD2-mutant leukemia, we employed an integrated approach combining computational prediction with epigenetic compound library screening. This approach identified G9a inhibitors as promising candidates, capable of reversing gene expression signatures associated with Setd2 deficiency and selectively inhibiting SETD2-deficient cells.
View Article and Find Full Text PDF